Adaptive Treatment Regimens through Titration and Interval Scaling

32 concepts28 papers

Standard medical protocols often rely on a "one-size-fits-all" approach, where patients receive fixed doses at fixed intervals. However, biological diversity—ranging from genetic variations in drug metabolism to fluctuating disease activity—frequently renders these rigid schedules suboptimal. Neubauer et al. demonstrate that nearly one-third of patients may fail to respond to standard antiplatelet therapy due to inherent resistance, highlighting the need for a "test and treat" framework that adjusts medication based on individual physiological feedback.

Research across diverse fields, from ophthalmology to oncology, has converged on a more dynamic strategy: adaptive treatment regimens. These protocols replace static dosing with a feedback loop that titrates intensity and scales intervals based on real-time patient response.

The Titration Phase: Finding the Individual Threshold

The first step in an adaptive regimen is often a structured titration period. Rather than starting at a high maintenance dose, clinicians incrementally adjust the treatment intensity to identify the minimum effective level for a specific patient. Huang et al. et al. utilize this approach in ADHD treatment to identify optimal maintenance levels before beginning fixed-duration phases, ensuring that efficacy is measured at a stable, individualized dosage.

This concept extends beyond pharmacology to physiological stimulation. In the context of Magnetic Seizure Therapy, Jiang et al. and Xiang et al. describe titration protocols that incrementally increase stimulation parameters—such as frequency or duration—until a specific therapeutic marker is reached. This ensures the treatment meets the individual's physiological threshold while minimizing unnecessary exposure to high-intensity stimuli.

Treat and Extend: Scaling Intervals Based on Stability

Once a patient is stable, the focus shifts from finding the dose to optimizing the frequency of administration. The "treat-and-extend" regimen is a proactive maintenance strategy that dynamically adjusts the time between interventions.

In chronic retinal conditions, Siedlecki et al. and Luft et al. describe a process where the interval between injections is extended if the anatomy remains stable and shortened if disease activity recurs. The goal is to identify the maximum treatment-free interval that maintains health, thereby reducing the clinical burden on the patient. Eckardt et al. show that switching to therapies with dual-pathway inhibition can facilitate this scaling, increasing the time between treatments by over 50% while maintaining stable visual outcomes.

Proactive vs. Reactive Adjustment

Adaptive regimens can be categorized by their primary driver: managing toxicity (proactive) or managing recurrence (reactive).

  • Proactive Titration: In cancer therapy, Wang et al. and Burkhard-Meier et al. argue that proactive dose reductions based on individual tolerance actually improve long-term outcomes. By adjusting the dose to mitigate low-grade toxicities, clinicians can prevent total treatment discontinuation, keeping patients on beneficial therapies for longer durations.
  • Reactive Supplemental Dosing: Conversely, "as-needed" or pro re nata (PRN) strategies trigger interventions only when specific clinical indicators appear. Ji et al. and Li et al. demonstrate that basing repeat doses on objective signs of recurrence—such as new bleeding or fluid leakage—allows for high success rates with a significantly reduced number of procedures.

Modeling Non-Linear Treatment Paths

The shift toward adaptive dosing requires new ways to represent and predict medical interventions. Traditional databases often struggle with the inherent flexibility of "as-needed" prescriptions. Karystianis et al. developed text-mining systems to capture this variability, modeling minimum and maximum values for dose and frequency to better reflect real-world practice.

Furthermore, Parikh et al. suggest that optimal treatment regimes are often non-linear. In high-stakes environments like the ICU, the authors found that standardized escalation strategies can be counterproductive. Instead, policies that tailor dosage intensity to symptom severity—sometimes reducing medication for mild symptoms while maintaining aggression for severe cases—can significantly improve clinical outcomes. By integrating clinical judgment with these adaptive frameworks, as noted by Lin et al., practitioners can move beyond rigid protocols toward a truly personalized therapeutic maintenance.

History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_treat_and_extend_regimen_52f28627,
  title = {treat-and-extend regimen},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/treat-and-extend-regimen/rdr_52f28627f5464f08aa0c4afe5730b5b9},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}

This exact version (version 1, frozen text):

@misc{lacuna_treat_and_extend_regimen_52f28627_v1,
  title = {treat-and-extend regimen},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/treat-and-extend-regimen/rdr_52f28627f5464f08aa0c4afe5730b5b9/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-21},
}

See something wrong? Report a mistake